awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q50119590-391AD5F9-0E5A-433C-8C3D-9469CCEF80BC
Q50119590-391AD5F9-0E5A-433C-8C3D-9469CCEF80BC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50119590-391AD5F9-0E5A-433C-8C3D-9469CCEF80BC
Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
P2860
Q50119590-391AD5F9-0E5A-433C-8C3D-9469CCEF80BC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50119590-391AD5F9-0E5A-433C-8C3D-9469CCEF80BC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5d8f8ba29ff3dd0c4ed47173e527bd3e87d3fc67
P2860
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.